Evidence map›Paper›PMID 39172856›Full record

ArticleScience (New York, N.Y.)2024

Alzheimer's and metabolism wed with IDO1.

Lance A Johnson, Shannon L Macauley

Abstract readNewsComment
In one paragraph

Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Lance A JohnsonDepartment of Physiology, University of Kentucky, Lexington, KY 40508 USA.
Shannon L MacauleyDepartment of Physiology, University of Kentucky, Lexington, KY 40508 USA.

Funding

Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathiesP20GM148326 · NIGMS · UNIVERSITY OF KENTUCKY · PI Patrick G Sullivan · 2023 to 2026
$10.6M
The metabolic interplay of sleep and Alzheimer's diseaseR01AG068330 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MACAULEY-RAMBACH, SHANNON L · 2020 to 2024
$3.5M
APOE Allele Switching as a Therapeutic Approach for Alzheimer's DiseaseR01AG080589 · NIA · UNIVERSITY OF KENTUCKY · PI Lance Allen Johnson · 2023 to 2026
$2.6M
Assessing the role of APOE in glial lipid droplet metabolism and functionR01AG081421 · NIA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sarah Cohen, Lance Allen Johnson · 2023 to 2026
$2.4M
Examining the Effects of the Neuroprotective APOE2 Allele on Peripheral ImmunometabolismR01AG062550 · NIA · UNIVERSITY OF KENTUCKY · PI JOHNSON, LANCE ALLEN · 2019 to 2023
$2.2M
NIA NIH HHS R01 AG062550NIA NIH HHS R01 AG068330NIA NIH HHS R01 AG080589NIA NIH HHS R01 AG081421NIGMS NIH HHS P20 GM148326
6 · The paper itself

Abstract

Kynurenine pathway inhibition reverses deficits in Alzheimer's mouse models.

Indexed as

Alzheimer DiseaseIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineAmyloid beta-PeptidesAnimalsDisease Models, AnimalHumansMiceTryptophanAmyloid beta-PeptidesIDO1 protein, mouseIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineTryptophan

Identifiers

PMID39172856
PMCPMC11661799

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.